Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.
Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.
Prithviraj Bose, MD, discusses...